Multi-center Clinical Study on Hemoperfusion of KHA80

Inclusion Criteria: 1. Age ≥18 years old, regardless of sex; 2. According to the 2012 KDIGO guidelines, it was diagnosed as CKD5 (EGFR ≦ 15ml/(min ˙ 1.73m2)); 3. receive regular hemodialysis (including hemodialysis filtration) for 4 hours twice a week for ≧3 months; 4. blood β 2-mg ≥ 30 mg/L and/or PTH ≥ 600 pg/mL and/or IL-6 ≥ 16.2 pg/mL; 5. Sign the informed consent form. Exclusion Criteria: 1. Those who are known to have allergic reactions, contraindications or intolerance to the materials of dialyzers and hemoperfutors; 2. Patients with severe bleeding tendency and active bleeding, or with definite coagulation dysfunction, with a platelet count of \< 60× 109/L; 3. Hemodialysis blood flow \< 200 ml/min. 4. Kt/V\<1.2； 5. Serum albumin \< 30g/L; 6. Parathyroid resection within one year; 7. people with low blood pressure and severe cardiopulmonary insufficiency; 8. lactating or pregnant women or those who plan to be pregnant within one year; 9. infection, history of malignant tumor, active stage of rheumatic immune disease; 10. Patients whose life expectancy is less than one year; 11. Other clinical researchers are currently or recently (within 30 days); 12. According to the researcher's judgment, the patient has other unsuitable conditions.